-
Mashup Score: 18
Colchicine and prednisone exhibit equivalent short-term efficacy for the treatment of acute calcium pyrophosphate crystal arthritis, with different safety profiles in the older population.
Source: www.thelancet.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 3FDA Approves Olaparib Triplet for mCRPC - 11 month(s) ago
Findings from the phase 3 PROpel have led to the FDA approval of olaparib in combination with abiraterone and prednisone or prednisolone for a prostate cancer subgroup.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
BREAKING: The #FDA has approved #olaparib in combination with #abiraterone and #prednisone or #prednisolone for adult patients with #mCRPC. #pcsm | @DukeCancer @FDAOncology https://t.co/1Yc2JZjrER https://t.co/W7r5Qs1bKr
-
-
Mashup Score: 0PRESTO Follow-Up: Updated PFS on Androgen Annihilation | GU Oncology Now - 12 month(s) ago
A report presented at the AUA 2023 Annual Meeting described the PRESTO study’s extended follow-up results on androgen annihilation for relapsed prostate cancer.
Source: GU Oncology NowCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A recent report has detailed the phase 3 PRESTO study's extended follow-up results. The study examined intensified ADT and #apalutamide with or without abiraterone acetate plus #prednisone for the treatment of relapsed prostate cancer. Read more: https://t.co/Gq8TDlDoec https://t.co/UtNsw7tQ7S
-
-
Mashup Score: 0
Findings from the second interim analysis of the phase 3 MAGNITUDE study showed the positive benefit of niraparib plus abiraterone and prednisone in metastatic castration-resistant prostate cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In the second interim analysis of the phase 3 MAGNITUDE study, there was a positive benefit with #niraparib plus #abiraterone and #prednisone in metastatic castration-resistant prostate cancer. #mpcrc #pcsm #GU23 | @ASCO https://t.co/Pdz2IzeaX4
-
-
Mashup Score: 0Instagram - 1 year(s) ago
headachejournal 135 posts · 1,332 followers
Source: www.instagram.comCategories: Latest Headlines, NeurologyTweet-
New Instagram post! https://t.co/CcXZbDEXeG Is #prednisone still a reasonable option in tx of withdrawal #headache in patients w #chronicmigraine & #MedicationOveruseHeadache (#MOH) in the age of #CGRP antibodies? Open access manuscript linked below! #InstagramThursdays https://t.co/TTreAIq6Gd
-
-
Mashup Score: 0FDA Delays PDUFA Hearing for Olaparib/Abiraterone Combo in mCRPC - 1 year(s) ago
The FDA has told AstraZeneca and MSD that the agency will extend the Prescription Drug User Fee Act date by 3 months to provide further time for a full review of the supplementary new drug application for olaparib plus abiraterone and prednisone or prednisolone for patients with mCRPC.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI: @US_FDA has told AstraZeneca and MSD that the agency will extend the PDUFA date by 3 months to provide further time for a full review of the sNDA for #olaparib plus #abiraterone and #prednisone or prednisolone for patients with mCRPC. #pcsm https://t.co/rw2T9AuOHU
-
-
Mashup Score: 1FDA Delays PDUFA Hearing for Olaparib/Abiraterone Combo in mCRPC - 1 year(s) ago
The FDA has told AstraZeneca and MSD that the agency will extend the Prescription Drug User Fee Act date by 3 months to provide further time for a full review of the supplementary new drug application for olaparib plus abiraterone and prednisone or prednisolone for patients with mCRPC.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI: @US_FDA has told AstraZeneca and MSD that the agency will extend the PDUFA date by 3 months to provide further time for a full review of the sNDA for #olaparib plus #abiraterone and #prednisone or prednisolone for patients with mCRPC. #pcsm https://t.co/9f47Gh5gP8 https://t.co/LoltwruJTv
-
-
Mashup Score: 0Prednisone bests anakinra, zinc for 90-day survival in severe alcohol-related hepatitis - 1 year(s) ago
WASHINGTON — Prednisone induced a higher 90-day survival rate and lower incidence of acute kidney injury compared with anakinra and zinc sulfate in patients with severe alcohol-associated hepatitis, according to late-breaking data. “Alcohol-associated hepatitis (AH) is an acute clinical syndrome resulting from heavy and sustained alcohol consumption. Severe AH has a 90-day mortality
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#Prednisone bests #anakinra, #zinc for 90-day survival in severe alcohol-related #hepatitis #TLM2022 #LiverMtg22 #LiverTwitter https://t.co/CfCm5JSpWr
-
-
Mashup Score: 1Tocilizumab and Disease Activity in Patients With Polymyalgia Rheumatica Receiving Glucocorticoid Therapy - 2 year(s) ago
This randomized clinical trial compares the effect of intravenous infusions of tocilizumab vs placebo on patients with polymyalgia rheumatica who were receiving glucocorticoid therapy.
Source: jamanetwork.comCategories: Latest Headlines, RheumatologyTweet-
In active #PolyMyalgiaRheumatica on #glucocorticoid, addition of #tocilizumab leads to ✅Improved disease activity ✅Reduced #prednisolone dosage 👉🏽https://t.co/W9pns2LUNO via @JAMANetwork #PMR #prednisone https://t.co/voRF7cMGmp
-
-
Mashup Score: 0
Long-term corticosteroids during pregnancy is associated with maternal and fetal adverse outcomes which may influence the insulin resistance later in life.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
Children who were exposed to low dose #prednisone in utero had no increased risk for insulin resistance in early childhood (from infancy through approximately 7 years). https://t.co/gHA8e5YcSD
-
NEW RESEARCH—In an open-label, multicentre, randomised trial, #colchicine and #prednisone exhibited equivalent short-term efficacy for the treatment of acute calcium pyrophosphate crystal arthritis in older patients https://t.co/RmGwIUdK03 #CPPD https://t.co/3FtDwk2OUf